GILD

Gilead Sciences
D

GILD

88.620
USD
0.89
(1.01%)
مغلق
حجم التداول
0
الربح لكل سهم
4
العائد الربحي
3.66
P/E
109
حجم السوق
110,331,198,218
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
الأفكار والتحليلات
    هشام منسي
    هشام منسي
    منذ 3 أسابيع
    buy
    GILD
    GILD
    2024-10-30 14:50
    GILD Chart
    المزيد
أصول ذات صلة
    ABBV
    ABBV
    -4.630
    (-2.73%)
    167.72 USD
    AMGN
    AMGN
    -12.22
    (-4.13%)
    287.81 USD
    BIIB
    BIIB
    -4.840
    (-2.94%)
    160.000 USD
    BMY
    BMY
    -2.270
    (-3.88%)
    56.230 USD
    GSK
    GSK
    -1.020
    (-2.97%)
    33.350 USD
    JNJ
    JNJ
    2.140
    (1.41%)
    153.1 USD
    MRK
    MRK
    -2.050
    (-2.08%)
    97.43 USD
    PFE
    PFE
    -1.225
    (-4.71%)
    24.945 USD
    REGN
    REGN
    -25.40
    (-3.25%)
    756.82 USD
    المزيد
الأخبار

العنوان: Gilead Sciences

القطاع: Healthcare
الصناعة: Drug Manufacturers - General
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).